TP
ARCT icon

TritonPoint Partners’s Arcturus Therapeutics ARCT Stock Holding History

TritonPoint Partners’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$189K Buy
28,186
+114
+0.4% +$899 0.02% 345
2026
Q1 		$217K Hold
28,072
– – 0.08% 189
2025
Q4 		$172K Buy
+28,072
New +$303K 0.09% 149

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

TritonPoint Partners's ARCT Position: Q2 2026 in Review

TritonPoint Partners increased its Arcturus Therapeutics (ARCT) stake by 0.41% in Q2 2026, buying an estimated $899 and bringing the position to 28,186 shares worth $189K. The position accounts for 0.02% of the portfolio, ranked #345.

TritonPoint Partners first reported a position in ARCT in Q4 2025 and has held it in 3 quarters since. The position peaked at $217K in Q1 2026. 134 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • TritonPoint Partners held 28,186 shares of Arcturus Therapeutics worth $189K as of Q2 2026.
  • TritonPoint Partners bought 114 Arcturus Therapeutics shares in Q2 2026, an estimated $899.
  • Arcturus Therapeutics made up 0.02% of TritonPoint Partners's portfolio in Q2 2026, its #345 holding.
  • TritonPoint Partners first reported a position in Arcturus Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • TritonPoint Partners's Arcturus Therapeutics position peaked at $217K in Q1 2026.
  • 134 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on TritonPoint Partners's 13F filing for Q2 2026, filed 13 Aug 2026.